



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 September 2013
EMA/CVMP/524600/2013
Committee for Medicinal Products for Veterinary Use

Summary of opinion¹ (post-authorisation)

Equip WNV

Common name: Vaccine to aid in prevention of West Nile virus

On 12 September 2013, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion², recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Equip WNV. The marketing authorisation holder for this veterinary medicinal product is Zoetis Belgium SA.

The change agreed by the CVMP concerns the addition of an indication against West Nile virus lineage 2 strains.

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SPC) which will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

